In prostate cancer, docetaxel-treated cells secrete CSF-1 to recruit TAMs, which then activate CXCR4 signaling via CXCL12 secretion, promoting tumor cell survival and resistance to chemotherapy (117). Here, CXCL12 is linked to prostate carcinoma.